PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

开始日期2026-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT06868381

/ Not yet recruiting临床2期IIT

A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
* Visit the clinic every two to four weeks for checkups and tests
* Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

开始日期2025-07-01

申办/合作机构

Stanford University

[+1]

NCT06923072

/ Recruiting临床2期IIT

A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients With Neurological Involvement

Background:
Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D lesions throughout the body, affecting the skin, lungs, heart, spinal cord, and brain. KD can be fatal. No treatment exists for this disease.
Objective:
To test a study drug (baricitinib) in people with brain and spine lesions caused by KD disease. Baricitinib is FDA approved to treat other disorders but has not yet been tried in people with KD.
Eligibility:
People aged 18 years or older with KD-related lesions in the brain and spine.
Design:
Participants will be screened; they will have a physical exam with blood tests. They will also have a baseline visit that may include multiple tests, such as imaging scans of the brain and spine; a lumbar puncture to collect fluid from the spinal canal; and a meeting with a neurologist. They will fill out a questionnaire about their health. They will continue to take their normal medications throughout the study.
Baricitinib is a tablet taken by mouth. Participants will remain on their normal medications for 12 weeks after their baseline visit. Then they will also take the study drug once a day at home for 24 weeks.
Participants will have clinic visits every few weeks for up to 40 weeks. Some visits may take 1 to 4 days. Baseline tests will be repeated 3 more times during study visits. Other visits will require only blood tests; these may be done by local labs that will send the samples to NIH; 2 visits may be done via telehealth....

开始日期2025-07-01

申办/合作机构

National Heart, Lung & Blood Institute

100 项与巴瑞替尼相关的临床结果

登录后查看更多信息

100 项与巴瑞替尼相关的转化医学

登录后查看更多信息

100 项与巴瑞替尼相关的专利（医药）

登录后查看更多信息

3,625

项与巴瑞替尼相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials

Review

作者: Lv, Xiaoqing ; Ji, Chao ; Mao, Jing ; Qin, Kun ; Ou, Yushan ; Ruan, Shifan ; Su, Xinhong

BACKGROUND:

Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs).

OBJECTIVES:

To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs.

METHODS:

PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study.

RESULTS:

Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I²=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (p = .56) or medication (p = .69).

CONCLUSIONS:

This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice.

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation

Letter

作者: Flinn, A M ; Browne, F ; Blokhuis, C ; Irvine, A D ; Leahy, T R

2025-12-01·Current Hematologic Malignancy Reports

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Review

作者: Harrington, Patrick ; Palumbo, Giuseppe A ; Chifotides, Helen T ; Duminuco, Andrea ; Bose, Prithviraj ; Torre, Elena ; Vetro, Calogero

PURPOSE OF REVIEW:

In this review, we highlight conventional agents and novel emerging therapeutic strategies to treat anemia in MF.

RECENT FINDINGS:

Anemia is a common and challenging feature of myelofibrosis (MF). The pathobiology of anemia is multifactorial, including progressive bone marrow fibrosis, decreased erythropoiesis due to high hepcidin levels leading to iron sequestration in the reticuloendothelial system, hypersplenism, erythropoiesis inhibition by myelosuppressive JAK inhibitors (ruxolitinib, fedratinib), and others. MF-associated anemia has a negative impact on survival. Conventional agents to manage anemia include erythropoiesis-stimulating agents, danazol, corticosteroids, and immunomodulatory agents, but responses are infrequent and lack durability. Notable advancements have emerged in developing novel treatments for anemia in MF, including the regulatory approval of momelotinib (ACVR1/JAK1/2 inhibitor) in 2023 and development of novel promising agents targeting hemojuvelin and activins. Momelotinib and pacritinib (ACVR1/JAK2 inhibitor) are the preferred JAK inhibitors for patients with cytopenias (anemia, thrombocytopenia). Luspatercept and elritercept are activin receptor ligand traps, promoting erythroid maturation and late-stage erythropoiesis. Currently, luspatercept is being evaluated in a phase 3 trial (INDEPENDENCE™) for anemia in MF patients who are on a JAK2 inhibitor and require transfusions, and in a phase 2 trial (ODYSSEY) in combination with momelotinib in MF patients who are transfusion dependent, whether or not on a JAK inhibitor. Interim results of the RESTORE trial demonstrated that elritercept significantly decreased transfusions in MF patients. DISC-0974 is a first-in-class anti-hemojuvelin (positive hepcidin regulator) monoclonal antibody that decreased hepcidin expression, increased serum iron, and enhanced erythropoiesis in anemic patients with MF in a phase 1b/2 study. Burgeoning studies of novel anemia-targeted agents and combinations are significantly improving the quality of life and outcomes of patients with MF. The recent approval of momelotinib to treat MF with anemia and the emerging novel anemia-directed strategies in early and advanced clinical development have ushered in a new era in the treatment of MF-related anemia.

987

项与巴瑞替尼相关的新闻（医药）

2025-06-23

·药明康德

可恢复80%头发生长！创新疗法如何改写这类脱发的治疗格局？

编者按：斑秃是一种自身免疫性疾病，是全球发病率第二高的脱发类型。目前，全球约有3000多万斑秃患者，其典型临床特征为局部或全身性脱发，这些症状往往给患者，尤其是青少年群体的生活带来极大困扰。20世纪50年代，科学界首次提出斑秃的自身免疫机制理论，并将糖皮质激素引入临床治疗，随后免疫抑制剂也逐渐成为斑秃的治疗选择。然而，传统斑秃疗法面临复发率高和靶向性不足的困境，这一瓶颈直到JAK抑制剂的应用才得以改变：2022年6月，FDA批准首款系统性斑秃疗法——口服JAK1/2抑制剂baricitinib；次年6月，JAK3/TEC抑制剂ritlecitinib获批，该疗法是FDA批准的首款用于治疗青少年的斑秃疗法；2024年7月，FDA批准又一款JAK1/2抑制剂deuruxolitinib，用于成人中重度斑秃的治疗。这些突破性疗法的问世显著丰富了斑秃的临床选择。如今，JAK抑制剂已成为治疗斑秃的经典靶点，与此同时更多创新靶点持续涌现，更多元化的分子管线也在临床开发中，未来有望为斑秃患者群体带来更多治疗选择。这些进展的背后，凝聚着科学家们、医药企业和创新药生态圈的智慧与汗水。长久以来，药明康德也一直在支持各类自身免疫性疾病靶向疗法的开发，用“一体化、端到端”的CRDMO服务持续赋能，助力合作伙伴加速更多好药新药问世。在ritlecitinib获批两周年之际，本文将带领读者一同回顾这款疗法的研发历程，以及斑秃疗法的创新之旅。图片来源：123RF作为一款突破性疗法，早在其正式获批之前，ritlecitinib就已经在临床试验中改变了众多斑秃患者的生活。玛丽亚·斯特拉特纳（Maria Strattner）就是其中一位受益者——在13岁时，她的斑秃症状在短短两周内急剧恶化，甚至失去了包括睫毛和眉毛在内的所有毛发。这一度让她的生活陷入低谷，但她和母亲并未放弃希望。她们最终在耶鲁大学了解到ritlecitinib的临床试验，并于2020年参与其中。令人振奋的是，使用ritlecitinib仅仅几个月后，玛丽亚的头发就开始重新生长，她的生活重回正轨。如今，ritlecitinib已在美国、欧盟、中国、日本等全球多个国家和地区获批上市，为数以万计的斑秃患儿及其亲属带来新的希望。图片来源：123RF从炎症疾病到斑秃治疗的跨领域突破在医学领域，斑秃一直是个棘手的难题。斑秃是一种自身免疫性疾病，免疫系统会错误地将毛囊当作敌人进行攻击，导致局部或广泛的脱发。在过去很长一段时间里，医学界始终没有找到有效的系统性治疗方案，直到JAK抑制剂出现，才为斑秃的治疗带来了新的希望。2014年，时任耶鲁大学医学院皮肤病学助理教授的布雷特·金（Brett A. King）博士接诊了一位同时患有严重银屑病和普遍性脱发的年轻患者，这个身患两种自身免疫性疾病的棘手病例引起了他的思考：既然这两种疾病都源于免疫系统对正常组织的错误攻击，它们是否存在共同的致病机制？而此前一项研究发现为他带来了启发：彼时已获得FDA批准用于治疗类风湿性关节炎（同为自身免疫性疾病）的JAK抑制剂tofacitinib，在动物实验中成功让斑秃小鼠重新长出了毛发！图片来源：123RF从机制上看，JAK-STAT信号通路是细胞内多条促炎信号的共同枢纽。白介素（ILs）、干扰素（IFNs）等细胞因子都需要借助该通路完成从细胞膜到胞内的信号传递，进而参与自身免疫性疾病与炎症性疾病的病理过程。因此，靶向JAK-STAT通路、抑制JAK激酶活性，已成为治疗此类疾病的重要策略。当时，虽然JAK抑制剂在类风湿性关节炎、炎症性肠病（IBD）等疾病领域已展现出显著疗效，但其在斑秃治疗中的临床应用仍属空白。机制研究发现，这类药物可通过干扰促炎性细胞信号通路，抑制免疫系统对毛囊的异常攻击，从而促进毛发再生。King博士敏锐地联想到，既然tofacitinib在动物实验中已经显示出促进毛发再生的潜力，如果将它应用于斑秃的临床治疗，是不是也会有意外收获呢？治疗结果超出所有人预期：那位年轻患者不仅银屑病症状得到显著改善，更在短期内就观察到了毛发再生现象——治疗仅两个月后，患者曾7年“寸草不生”的头皮上开始萌生小绒毛。当加大剂量并持续用药三个月时，患者的眉毛、睫毛、胡须和腋毛也都全部重新生长。至治疗第8个月时，患者的头发已与常人无异。值得一提的是，整个治疗过程未引发患者任何不适反应，安全性表现优异。图片来源：123RF这一成功案例促使King博士及其团队系统性地开展JAK抑制剂治疗斑秃的临床研究，从经典JAK抑制剂药物tofacitinib和ruxolitinib的口服及外用制剂着手，逐步验证了这类药物在斑秃治疗中的临床价值。然而，随着研究的深入，研究人员发现，这些经典JAK抑制剂在斑秃治疗领域虽然有效，但存在需要大剂量长期使用、停药易复发等问题。这一现状促使研究人员寻求更优解决方案。转机出现在2018年——礼来和Incyte公司联合开发的JAK1/2抑制剂baricitinib被FDA的批准用于治疗类风湿性关节炎。这款药物在安全性和有效性方面展现出显著优势，因此King博士团队迅速将其纳入斑秃治疗研究，评估其作为经典JAK抑制剂替代方案的潜力。研究结果远超预期：在King博士主导的两项纳入约1200名严重斑秃患者的大型临床试验中，每日仅4 mg剂量的baricitinib治疗就使三分之一患者实现了80%以上的头发再生！基于突破性的临床成果，baricitinib于2022年6月获得FDA批准用于治疗严重斑秃成人患者，成为FDA批准的首个用于治疗斑秃的系统性疗法。为青少年患者打造的斑秃药物尽管baricitinib的问世为斑秃患者提供了新的治疗选择，但未成年患者群体仍面临巨大的未满足临床需求。青少年时期是人生发展的关键阶段，斑秃的突发可能会对这些患者及其家庭造成深远影响。一些孩子会出现社交回避行为，减少社会交往甚至中断学业，伴随而来的严重焦虑和抑郁症状更是常见的精神共病。King博士长期投身于斑秃的临床治疗工作，在与众多斑秃少年患者的接触中，他深切体会到这类患者对有效疗法的迫切需求。因此，当辉瑞（Pfizer）就新型JAK3/TEC双激酶抑制剂ritlecitinib寻求临床试验合作时，King博士欣然接受了合作邀请，并在研究方案中特别纳入100余名青少年患者，以期填补这一特殊人群的治疗空白。Ritlecitinib作为一款新型双激酶抑制剂，可选择性抑制JAK3及TEC激酶家族。相较于JAK的另外两种亚型（即JAK1/JAK2），ritlecitinib对JAK3表现出了高选择性，这源于其与JAK3中Cys-909残基的不可逆共价结合——该位点在其他JAK亚型中均被丝氨酸残基取代。值得注意的是，由于TEC激酶家族在JAK3的Cys-909等效位置同样含有半胱氨酸残基，使得ritlecitinib也可同步抑制该家族激酶。除双靶点抑制特性外，ritlecitinib在全激酶组范围内也展现出高度选择性，为其临床安全性提供了理论基础。▲Ritlecitinib分子结构式（图片来源：PubChem）为验证该药物在斑秃患者（尤其是青少年群体）中的安全性与疗效，King博士牵头开展了一项覆盖18个国家的关键性2b/3期临床试验。该研究共招募600余名成年患者（≥18岁）及100余名青少年患者（12-17岁），所有受试者头发脱落程度均≥50%。数据显示，治疗6个月时，约23%的患者的头发覆盖率≥80%（安慰剂组仅1.6%），且达标患者比例随用药时间持续增加。更重要的是，该药物在成人与青少年患者中展现出一致的疗效与良好耐受性。基于这一结果，FDA于2023年6月批准ritlecitinib上市，用于治疗12岁以上严重斑秃患者——这也是FDA首次批准用于重度斑秃青少年（12+）患者的治疗药物。目前，辉瑞正持续拓展ritlecitinib的临床适应症。除斑秃外，针对中重度溃疡性结肠炎、克罗恩病、白癜风、类风湿关节炎等炎症性疾病的相关临床试验已陆续开展。未来可期：更多创新疗法蓄势待发在ritlecitinib获批之后，King博士在采访中曾表示：期待未来有更多药物获批用于斑秃治疗。如今，这一期待正逐步成为现实。从全球研发态势来看，斑秃治疗领域正迎来快速发展期。根据公开信息，目前全球约有70款在研新药处于不同开发阶段，其中多款已进入临床试验。这些在研药物的作用靶点也呈现出多元化趋势：除JAK靶点外，针对S1PR家族、OX40、LILRA4等创新靶点的探索，正在不断拓展临床治疗选择。图片来源：123RF多款创新药物已取得重要临床进展。其中，OX40单抗IMG-007在重度斑秃患者的2a期试验中展现出剂量依赖性的持续疗效，高剂量组患者在治疗24周后脱发严重程度评分（SALT）平均降低14.3%，至36周时进一步降低至21.7%，且未观察到疗效平台期。该药物的安全性表现同样令人鼓舞，未报告严重不良事件。与此同时，LILRA4单抗daxdilimab已完成2期试验，OX40L单抗amlitelimab和调节性T细胞（Treg）调控剂rezpegaldesleukin也已完成2期临床患者招募。此外，靶向IL-7Rα的bempikibart于今年4月获得FDA快速通道资格，用于治疗斑秃。目前该疗法针对斑秃的2期临床研究正在进行中。这些针对不同靶点的创新疗法不仅丰富了治疗选择，也为深入理解斑秃的发病机制提供了新的研究方向。已获批的JAK抑制剂也在拓展新的治疗领域。艾伯维（AbbVie）的JAK1抑制剂upadacitinib正在开展斑秃3期研究，而baricitinib在青少年严重斑秃患者中显示出显著疗效——3期试验数据显示，超过20%的受试者实现了90%以上的头发再生率。若该药物能进一步获批用于青少年患者群体，有望成为斑秃治疗领域的又一重要里程碑。当前，斑秃药物研发领域已取得显著进展，这些研发突破的背后，离不开医药产业链各环节的协同创新。作为全球医药创新的赋能者，药明康德多年来凭借独特的一体化、端到端的CRDMO模式，为全球创新合作伙伴提供从研究（R）、开发（D）、到商业化生产（M）的全流程服务，并在自身免疫性疾病靶向疗法治疗领域助力多款新药的研发。我们相信，随着全球科研力量的持续投入和创新技术的不断突破，更多安全有效的创新疗法将为全球斑秃患者带来更加丰富的治疗选择。参考资料（可上下滑动查看）[1] FDA approves 1st treatment that can grow back hair for teens with severe alopecia areata. Retrieved May 21, 2025 from https://abcnews.go.com/GMA/Wellness/fda-approves-1st-treatment-grow-back-hair-teens/story?id=100325718[2] FDA approves second Yale-researched treatment for alopecia areata. Retrieved May 21, 2025 from https://news-yale-edu.libproxy1.nus.edu.sg/2023/06/26/fda-approves-second-yale-researched-treatment-alopecia-areata[3] Progress in search for alopecia areata treatment for adolescents. Retrieved May 21, 2025 from https://news-yale-edu.libproxy1.nus.edu.sg/2023/04/13/progress-search-alopecia-areata-treatment-adolescents[4] FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata. Retrieved May 21, 2025 from https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and[5] Xu, Hua et al. “PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.” ACS chemical biology vol. 14,6 (2019): 1235-1242. doi:10.1021/acschembio.9b00188[6] 国产JAK1抑制剂硫酸艾玛昔替尼片斑秃适应症上市申请获受理. Retrieved May 21, 2025 from https://mp.weixin.qq.com/s/qjNJ_Nw8Q0kBP4Y064Fgjg[7] NDA进展 I 泽璟制药吉卡昔替尼片治疗重度斑秃的新药上市申请获受理. Retrieved May 21, 2025 from https://mp.weixin.qq.com/s/M7uXhHWR6wGWeLISXoVcfA[8] In hairless man, arthritis drug spurs hair growth — lots of it. Retrieved May 21, 2025, from https://news-yale-edu.libproxy1.nus.edu.sg/2014/06/19/hairless-man-arthritis-drug-spurs-hair-growth-lots-it[9] Inmagene Reports Topline Results from Phase 2a Study of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, in Patients with Alopecia Areata. Retrieved May 21, 2025, from https://www.globenewswire.com/news-release/2025/04/24/3067491/0/en/Inmagene-Reports-Topline-Results-from-Phase-2a-Study-of-IMG-007-a-Nondepleting-Anti-OX40-Monoclonal-Antibody-with-an-Extended-Half-life-in-Patients-with-Alopecia-Areata.html[10] Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata. Retrieved May 21, 2025, from https://www.prnewswire.com/news-releases/q32-bio-announces-fda-fast-track-designation-granted-to-bempikibart-adx-914-for-the-treatment-of-alopecia-areata-302441850.html[11] Broadley, David, and Kevin J McElwee. “A "hair-raising" history of alopecia areata.” Experimental dermatology vol. 29,3 (2020): 208-222. doi:10.1111/exd.14073[12] Wang, Etienne C E et al. “Novel therapies for alopecia areata: The era of rational drug development.” The Journal of allergy and clinical immunology vol. 141,2 (2018): 499-504. doi:10.1016/j.jaci.2017.10.028[13] Zhou, Jia et al. “Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021.” Journal of cosmetic dermatology vol. 24,3 (2025): e70076. doi:10.1111/jocd.70076免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法放射疗法临床研究

2025-06-23

·药事纵横

瀚合瑞：提供从立项到获批的全流程药学CRO服务 | 7thCMC-China优质推荐

上海瀚合瑞医药科技有限公司：提供制剂项目从立项到获批的全流程药学CRO服务，具备经验丰富的的固体制剂、液体制剂和半固体制剂研发团队，以及完备的工艺和分析研发设备。截至目前，团队已完成近200个仿制药和多个创新药制剂研发服务，多个仿制药项目取得国内首仿或前三仿。上海瀚合瑞医药科技有限公司隶属于天津臻诺医药集团，集团下设上海、天津2大CMC研发中心，2大临床研究中心及临床数据统计中心，以及1家原料生产基地，拥有20多家战略合作原料药和制剂生产基地，员工人数超600人，可为客户提供原料药和制剂产品从项目立项、药学研究、临床研究、委托加工、注册申报到MAH产品运营全生命周期一站式服务。集团技术服务平台01 制剂技术平台● 固体制剂、注射剂、外用制剂全流程开发● 难溶性药物给药技术● 固体分散体技术● 高难度复方制剂开发平台● MAH合作/品种转让02 原料技术平台● 仿制及创新原料药CMC研究● 产品定制研发和生产服务（CDMO）● 含氟中间体和原料药平台● 不对称合成、生物酶催化、连续化等技术应用03 临床技术平台 ● 临床药代动力学● 生物等效性● 临床实验方案设计及研究运营、覆盖Ⅰ-Ⅳ期及真实世界● 分析检测服务重点项目推荐奥匹卡朋胶囊01规格：25mg、50mg适应症：左旋多巴/卡比多巴的辅助治疗，适用于帕金森病(PD)的“off”期发作研发进展：原料药&制剂联合开发，中试阶段多替诺雷片02规格：0.5mg、1mg、2mg适应症：痛风，高尿酸血症研发进展：原料药&制剂联合开发，验证批阶段布地奈德肠溶胶囊03规格：4mg适应症：具有进展风险的原发性IgA肾病成人患者研发进展：小试阶段富马酸依美斯汀缓释胶囊04规格：1mg、2mg适应症：过敏性鼻炎和荨麻疹研发进展：小试阶段盐酸米安色林片05规格：10mg，30mg适应症：治疗的各型抑郁症患者，能解除其抑郁症状研发进展：小试阶段西吡氯铵含片06规格：2mg适应症：用于急性、亚急性咽炎，牙龈炎研发进展：小试阶段地喹氯铵含片07规格：0.25mg适应症：用于急、慢性咽喉炎，口腔黏膜溃疡、齿龈炎研发进展：小试阶段苯磺酸美洛加巴林片/口崩片08规格：2.5mg、5mg、10mg、15mg适应症：糖尿病性周围神经病理性疼痛研发进展：小试阶段乌帕替尼缓释片&口服溶液09规格：片剂：15mg口服溶液：1mg/ml适应症：（片剂）特应性皮炎、类风湿关节炎、银屑病关节炎、溃疡性结肠炎等（口服溶液）2岁及以上患者银屑病关节炎、幼年特发性关节炎研发进展：验证批阶段巴瑞替尼片10规格：2mg、4mg适应症：类风湿关节炎、斑秃、特应性皮炎等研发进展：验证批阶段非奈利酮片11规格：10mg、20mg适应症：二型糖尿病相关的慢性肾病研发进展：原料药&制剂联合开发，审评中盐酸氮卓斯汀鼻喷雾剂12规格：10ml:10mg适应症：过敏性鼻炎研发进展：小试阶段非那雄胺喷雾剂13规格：2.275mg/ml适应症：用于 18 至 41 岁患有轻度至中度脱发（雄激素性脱发）的成年男性的局部治疗，以促进头发生长研发进展：小试阶段玛巴洛沙韦片/干混悬14规格：片剂：20mg、40mg干混悬剂：2mg/ml适应症：甲型和乙型流感研发进展：原料药&制剂联合开发，小试阶段醋酸地非法林注射液15规格：50μg/ml适应症：接受血液透析的患者，治疗慢性肾脏病相关的中度至重度瘙痒（CKD-aP）研发进展：中试阶段注射用西维来司他钠16规格：100mg适应症：用于改善全身性炎症反应综合征的急性肺损伤/急性呼吸窘迫综合征研发进展：小试阶段注射用氨曲南阿维巴坦钠17规格：1.5 g/0.5 g适应症：用于治疗复杂盆腔感染（cIAI）、复杂尿路感染（cUTI）、医院获得性肺炎（HAP）/呼吸机相关肺炎（VAP）等研发进展：小试阶段注射用盐酸依拉环素18规格：50mg适应症：适用于治疗成人复杂性腹腔感染（cIAI）研发进展：小试阶段依达拉奉右莰醇注射用浓溶液19规格：5ml:依达拉奉10mg与右莰醇2.5mg适应症：用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和功能障碍研发进展：验证批阶段苹果酸奈诺沙星氯化钠注射液20规格：250mll:苹果酸奈诺沙星0.5g与氯化钠 2.25g适应症：成人社区获得性肺炎研发进展：待申报注射用磷酸左奥硝唑酯二钠21规格：0.125g、0.5g、1g适应症：肠道和肝脏严重的阿米巴病、敏感厌氧菌感染引起的手术后感染等研发进展：中试阶段甲苯磺酸奥马环素片&注射用甲苯磺酸奥马环素22规格：片剂150mg、注射剂100mg适应症：社区获得性细菌性肺炎感染、急性细菌性皮肤和皮肤结构感染研发进展：待申报注射用亚胺西瑞23规格：1.25g（亚胺培南500mg+西司他丁500mg+瑞来巴坦250mg）适应症：成人医院内获得性细菌性肺炎和呼吸机相关性细菌性肺炎、复杂性尿路感染、复杂性腹腔内感染研发进展：小试阶段呋喹替尼胶囊24规格：1mg、5mg适应症：结直肠癌研发进展：原料药&制剂联合开发，小试阶段阿帕他胺片25规格：60mg适应症：非转移性去势抵抗性前列腺癌及转移性去势敏感性的前列腺癌研发进展：原料药&制剂联合开发，审评中注射用卡非佐米26规格：60mg适应症：难治性多发性骨髓瘤研发进展：原料药&制剂联合申报，审评中阿贝西利片27规格：50mg、100mg、150mg适应症：早期乳腺癌；局部晚期或转移性乳腺癌研发进展：原料药&制剂联合开发，中试阶段妥卡替尼片28规格：50mg、150mg适应症：乳腺癌研发进展：原料药&制剂联合开发，中试阶段注射用盐酸美法仑29规格：50mg适应症：多发性骨髓瘤研发进展：中试阶段部分已有开发经验制剂品种联系我们周女士 13306586060嵇女士 15706844213张文静 15262236582大会详情 /CMC-CHINA点击下方图片了解更多▼

临床结果申请上市上市批准

2025-06-12

·EINPresswire

Giant-Cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight

The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ’s approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. New York, USA, June 12, 2025 (GLOBE NEWSWIRE) -- Giant-cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ’s approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. Giant-cell arteritis, also known as "Temporal Arteritis," is an inflammation of the arterial walls. It primarily affects arteries in the head, especially those near the temples, which is why it is often called temporal arteritis. In this condition, the temporal arteries, located on the sides of the head just in front of the ears, become inflamed. This inflammation causes the arteries to narrow, leading to reduced blood flow. According to DelveInsight’s analysis, patients over 80 years old represented the largest group of those living with giant-cell arteritis in the 7MM during 2023. The primary aim of treatment is to prevent serious complications, such as blindness. The standard therapy involves administering high doses of corticosteroids like prednisone, and prompt treatment is crucial to avoid vision loss or stroke. Learn more about the GCA treatment @ New Treatment for Giant-Cell Arteritis ACTEMRA/ROACTEMRA (tocilizumab) is a pioneering anti-IL-6 receptor (aIL-6R) therapy. Interleukin-6 (IL-6) is thought to be a major contributor to the inflammatory processes underlying rheumatoid arthritis (RA) and other autoimmune inflammatory diseases. By binding to and blocking the IL-6 receptor, ACTEMRA/ROACTEMRA helps reduce the activity of IL-6, leading to relief from joint pain, swelling, and other inflammation-related symptoms. The therapy is also approved for several other conditions, including pediatric juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), Giant-Cell Arteritis, and cytokine release syndrome (CRS) caused by CAR-T cell therapy. In September 2017, Roche announced that the European Commission (EC) approved ACTEMRA/ROACTEMRA for treating giant-cell arteritis, marking it as the first approved treatment for this condition in Europe. The decision was supported by results from the Phase III GiACTA study, which demonstrated that a weekly dose of the drug, combined with a six-month steroid taper, significantly improved sustained remission rates at one year, compared to steroid tapering alone. Later, in November 2018, Roche reported that the U.S. FDA approved the ACTPen autoinjector (162 mg/0.9 mL) as a new formulation of ACTEMRA for adult patients with giant-cell arteritis, offering an additional, more convenient administration option. Recently, in April 2025, AbbVie announced that the FDA had approved RINVOQ (upadacitinib) 15 mg, taken once daily, for treating adults with giant cell arteritis. This follows the recent marketing authorization granted by the European Commission for the same indication in adult patients. These approvals are based on data from the pivotal Phase 3 SELECT-GCA trial, which achieved its primary endpoint of sustained remission. Specifically, 46.4% of patients treated with RINVOQ 15 mg alongside a 26-week steroid taper reached sustained remission between weeks 12 and 52, compared to 29.0% of those on placebo with a 52-week taper (p=0.002). Throughout the 52-week, placebo-controlled study period, RINVOQ’s safety profile remained broadly consistent with its established safety in other approved uses. Find out more on FDA-approved GCA drugs @ Giant-Cell Arteritis Treatment Options Productive pharmacologic options for managing the most prevalent and most disabling phases of Giant-Cell Arteritis are minimal. Treatments that work in this disorder are scarce; therefore, new treatments are desperately needed. Some companies like Novartis (COSENTYX; secukinumab) and CSL/Kiniksa Pharmaceuticals (Mavrilimumab), among others, have initiated clinical trials that investigate new treatment options. Discover which therapies are expected to grab major GCA market share @ Giant-Cell Arteritis Market Report COSENTYX (secukinumab) is an injectable, fully human monoclonal antibody developed by Novartis Pharmaceuticals that targets and blocks interleukin-17A (IL-17A), a cytokine implicated in various immune-related disorders. It has received approval in both the United States and European Union for treating moderate-to-severe plaque psoriasis, active ankylosing spondylitis (AS) in adults, active non-radiographic axial spondyloarthritis (nr-axSpA), and active psoriatic arthritis (PsA) in adults. Secukinumab is an IgG1 monoclonal antibody that specifically binds to IL-17A, preventing its interaction with the IL-17 receptor. IL-17A plays a key role in regulating immune and inflammatory responses. By blocking this cytokine, secukinumab helps reduce the production of proinflammatory cytokines and chemokines. Novartis has completed a Phase II clinical trial for secukinumab in Giant-Cell Arteritis and is currently advancing the drug through Phase III trials for this indication. Discover more about drugs for GCA in development @ Giant-Cell Arteritis Clinical Trials The anticipated launch of these emerging therapies for GCA are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GCA market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for GCA is expected to grow from USD 960 million in the 7MM in 2023 at a significant CAGR by 2034. The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others. DelveInsight’s latest published market report, titled as Giant-Cell Arteritis Market Insight, Epidemiology, and Market Forecast – 2034 , will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the GCA country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market’s underlying potential. The GCA market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Giant-Cell Arteritis Total Subtype-specific Cases of Giant-Cell Arteritis Total Age group-specific Cases of Giant-Cell Arteritis Total Clinical Manifestation-specific Cases of Giant-Cell Arteritis Total Treated Cases of Giant-Cell Arteritis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM GCA market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert’s Opinion Access and Reimbursement Download this GCA market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs’ opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the GCA market. Also, stay abreast of the mitigating factors to improve your market position in the GCA therapeutic space. Related Reports Giant-Cell Arteritis Pipeline Giant-Cell Arteritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key giant-cell arteritis companies, including Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddys Laboratories, among others. Giant-Cell Arteritis Epidemiology Forecast Giant-Cell Arteritis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted giant-cell arteritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Rheumatoid Arthritis Market Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, among others. Rheumatoid Arthritis Pipeline Rheumatoid Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Amgen, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, among others. Rheumatoid Arthritis Epidemiology Rheumatoid Arthritis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted rheumatoid arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准临床3期临床2期免疫疗法临床结果

100 项与巴瑞替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10308	巴瑞替尼	L04AA37	DB11817

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
附着点炎相关关节炎	欧盟	Eli Lilly Nederland BV	2023-09-21
附着点炎相关关节炎	冰岛	Eli Lilly Nederland BV	2023-09-21
附着点炎相关关节炎	列支敦士登	Eli Lilly Nederland BV	2023-09-21
附着点炎相关关节炎	挪威	Eli Lilly Nederland BV	2023-09-21
幼年特发性关节炎	欧盟	Eli Lilly Nederland BV	2023-09-21
幼年特发性关节炎	冰岛	Eli Lilly Nederland BV	2023-09-21
幼年特发性关节炎	列支敦士登	Eli Lilly Nederland BV	2023-09-21
幼年特发性关节炎	挪威	Eli Lilly Nederland BV	2023-09-21
少关节关节炎	欧盟	Eli Lilly Nederland BV	2023-09-21
少关节关节炎	冰岛	Eli Lilly Nederland BV	2023-09-21
少关节关节炎	列支敦士登	Eli Lilly Nederland BV	2023-09-21
少关节关节炎	挪威	Eli Lilly Nederland BV	2023-09-21
多关节型幼年特发性关节炎	欧盟	Eli Lilly Nederland BV	2023-09-21
多关节型幼年特发性关节炎	冰岛	Eli Lilly Nederland BV	2023-09-21
多关节型幼年特发性关节炎	列支敦士登	Eli Lilly Nederland BV	2023-09-21
多关节型幼年特发性关节炎	挪威	Eli Lilly Nederland BV	2023-09-21
新型冠状病毒感染	瑞士	Eli Lilly & Co.	2017-06-19
斑秃	欧盟	Eli Lilly Nederland BV	2017-02-13
斑秃	冰岛	Eli Lilly Nederland BV	2017-02-13
斑秃	列支敦士登	Eli Lilly Nederland BV	2017-02-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
Aicardi-Goutieres综合征	临床3期	日本	Eli Lilly & Co.	2020-10-27
慢性非典型中性粒细胞性皮肤病伴脂肪营养不良和体温升高	临床3期	日本	Eli Lilly & Co.	2020-10-27
肢骨纹状肥大	临床3期	日本	Eli Lilly & Co.	2020-10-27
Nakajo综合征	临床3期	日本	Eli Lilly & Co.	2020-10-27
婴儿期发病的STING相关血管病变	临床3期	日本	Eli Lilly & Co.	2020-10-27
全身型幼年特发性关节炎	临床3期	日本	Eli Lilly & Co.	2020-02-12
全身型幼年特发性关节炎	临床3期	阿根廷	Eli Lilly & Co.	2020-02-12
全身型幼年特发性关节炎	临床3期	比利时	Eli Lilly & Co.	2020-02-12
全身型幼年特发性关节炎	临床3期	巴西	Eli Lilly & Co.	2020-02-12
全身型幼年特发性关节炎	临床3期	捷克	Eli Lilly & Co.	2020-02-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06662721 (Pubmed \| Rheumatology (Oxford))	临床2期	大动脉炎 TNF-α inhibitors	10	Baricitinib 4 mg daily	窪廠願遞壓築顧築齋構(窪範餘鹹餘觸夢構選構) = 構簾遞艱鑰選壓願築積鹽網齋繭鹹構淵蓋廠醖 (廠壓夢網觸憲鏇糧鹹顧 ) 更多	积极	2025-05-24
SLE-BRAVE-I and SLE-BRAVE-II (Pubmed \| PLoS One)	临床3期	系统性红斑狼疮	1,535	Baricitinib 4 mg	糧鹽遞餘網構膚網蓋衊(選繭夢網壓壓製製壓網) = 壓簾膚繭餘遞範鏇窪憲艱衊齋襯構網積鹹淵顧 (壓淵糧築網淵衊壓襯艱 )	不佳	2025-04-30
				Baricitinib 2 mg	糧鹽遞餘網構膚網蓋衊(選繭夢網壓壓製製壓網) = 鏇觸積窪襯衊構積構憲艱衊齋襯構網積鹹淵顧 (壓淵糧築網淵衊壓襯艱 )
BRAVE-AA1 and BRAVE-AA2 (Pubmed \| Am J Clin Dermatol)	临床3期	斑秃	1,303	Baricitinib 2 mg	簾襯繭構窪淵製艱遞衊(獵顧鑰憲鹽衊顧壓顧獵) = 網蓋積觸夢壓憲窪憲鏇簾鬱築鬱糧鑰廠糧艱齋 (構繭選鏇淵鏇簾鑰夢糧 ) 更多	积极	2025-04-11
				Baricitinib 4 mg	簾襯繭構窪淵製艱遞衊(獵顧鑰憲鹽衊顧壓顧獵) = 糧壓鑰鑰夢選齋鹽簾鹹簾鬱築鬱糧鑰廠糧艱齋 (構繭選鏇淵鏇簾鑰夢糧 ) 更多
BRAVE-AA1; BRAVE-AA2 (Pubmed \| Br J Dermatol)	N/A	斑秃	-	Baricitinib 2 mg	築憲網顧簾壓糧範齋簾(繭選餘壓鏇獵衊艱糧積) = 遞積願鏇遞壓鬱鹽積製積網鹹築壓獵製積顧壓 (窪願廠繭艱襯膚憲糧衊 )	积极	2025-04-03
				Baricitinib 4 mg	築憲網顧簾壓糧範齋簾(繭選餘壓鏇獵衊艱糧積) = 壓鹹觸構顧獵範鹹積製積網鹹築壓獵製積顧壓 (窪願廠繭艱襯膚憲糧衊 )
NCT05723198 (BRAVE-AA-PEDS, Company_Website) 人工标引	临床3期	斑秃	257	Baricitinib 4 mg	廠願齋夢願繭夢蓋簾蓋(餘壓繭艱醖鬱憲願餘膚) = 膚製範膚鹽鏇壓餘鏇鬱網積窪憲選艱製膚繭壓 (構襯醖築築醖衊鑰壓鏇 ) 更多	积极	2025-03-08
				Baricitinib 2 mg	廠願齋夢願繭夢蓋簾蓋(餘壓繭艱醖鬱憲願餘膚) = 蓋觸製鹹鹹膚鹹齋蓋窪網積窪憲選艱製膚繭壓 (構襯醖築築醖衊鑰壓鏇 ) 更多
NCT05188521 (Pubmed \| J Clin Invest)	临床2期	扁平苔藓 IFN-γ \| CD8+ \| CXCL13+	-	Baricitinib 2 mg	簾夢鹹壓淵築鑰鏇選繭(積窪窪顧構衊鹹顧願窪) = 網繭顧淵餘糧餘餘鑰製製鑰範選鬱選鹽遞構製 (遞鏇構窪淵繭願憲廠醖 )	积极	2025-01-16
NCT03952559 (BREEZE-AD-PEDS, Pubmed \| J Dermatolog Treat)	临床3期	中度特应性皮炎 \| 重度特应性皮炎	467	Baricitinib 4-mg equivalent	餘製願艱壓製獵築壓夢(觸願壓遞鏇構鏇範網構) = 窪鹽壓鹽範構鬱鬱鑰築艱製壓蓋衊壓鏇選獵蓋 (齋夢膚膚簾簾壓顧壓艱 )	积极	2024-12-31
NCT01885078 (RA-BEYOND, Pubmed \| Rheumatology (Oxford)) 人工标引	临床3期	类风湿关节炎	-	Baricitinib 4 mg	鹹築築遞製艱鑰繭壓淵(鬱鑰網構鬱築選糧選齋) = 鹹繭觸鬱襯積範膚憲構積窪築製鑰憲製齋憲餘 (製糧選艱繭餘選鹹遞醖 ) 更多	积极	2024-10-01
				Baricitinib 2 mg	鹹築築遞製艱鑰繭壓淵(鬱鑰網構鬱築選糧選齋) = 繭膚膚鑰憲夢蓋範鏇壓積窪築製鑰憲製齋憲餘 (製糧選艱繭餘選鹹遞醖 ) 更多
NCT04088409 (CTgov)	临床3期	前葡萄膜炎 \| 葡萄膜炎 \| 幼年特发性关节炎	30	Baricitinib (Baricitinib)	顧廠製憲積製鬱觸夢襯 = 夢築齋構構鑰鏇襯衊觸製選願蓋鏇選憲鹹積顧 (網製齋築糧獵獵鏇選廠, 鏇廠糧壓艱構廠醖襯築 ~ 壓鏇蓋鏇醖積獵鏇獵積) 更多	-	2024-08-13
				Adalimumab (Adalimumab)	構遞簾獵憲築膚簾醖鏇(糧糧選淵選艱觸製蓋選) = 願選鹹製艱壓膚衊顧淵艱襯鏇壓鏇衊顧醖製製 (遞壓夢製壓範夢淵繭鹹, 艱蓋遞膚衊襯壓觸夢鹽 ~ 築鹹襯觸襯衊鬱憲鹽製) 更多
NCT03570749 \| NCT03899259 (BRAVE-AA1; BRAVE-AA2, Pubmed)	临床3期	斑秃	131	Baricitinib 4 mg	廠鑰淵鬱簾醖鏇窪憲遞(鹽襯壓構鏇鹹製網窪蓋) = progressive improvements 衊淵繭觸願構膚鏇選構 (構選積選鏇鑰廠醖製鑰 ) 更多	积极	2024-06-21
				Baricitinib 2 mg